




<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>Cardiac Surgery and VHD</title>
        <link>http://www.acc.org/Feed?clinicalTopicID=f24e6d2b-ba21-4c56-871d-d44e86eba30b</link>
        <description>Clinical Topic Feed: Cardiac Surgery and VHD</description>
        <language>en</language>

        

                <item>
                    <title>Mission in Action | Medtronic Clinician Update on New Evolut Valve Data Reinforces Need For Patient Dialogue</title>
<link>/Latest-in-Cardiology/Articles/2026/04/01/01/Mission-in-Action-Medtronic-Clinician-Update</link>                    <description>New long-term data from the Evolut Low Risk trial published in JACC underscore how emerging science and evidence continue to shape patient-centered care in structural heart disease &#226;€“ an approach central to the ACC&#39;s Vision of using science, knowledge and innovation to optimize patient care and outcomes.</description>
                    <pubdate>1775045220000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>PRO-TAVI: Should High-Risk Patients Undergo PCI Before TAVI?</title>
<link>/Latest-in-Cardiology/Articles/2026/03/25/21/27/sun-4pm-protavi-acc-2026</link>                    <description>Older patients with coronary artery disease (CAD) for whom PCI was deferred until after TAVI had similar outcomes as those for whom it was not deferred, according to findings from the PRO-TAVI study presented in a Late-Breaking Clinical Trial session...</description>
                    <pubdate>1774818600000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>PROTECT H2H: Emboliner vs. Sentinel Embolic Protection Devices in TAVR</title>
<link>/Latest-in-Cardiology/Articles/2026/03/25/21/27/sun-4pm-protecth2h-acc-2026</link>                    <description>In the first head-to-head comparison of two embolic protection devices used during TAVR, the investigational Emboliner protection catheter performed comparably to the U.S. Food and Drug Administration (FDA)-approved Sentinel cerebral protection system relative to the composite primary endpoint and secondary endpoint of stroke, according to results from the PROTECT H2H trial presented during a Late-Breaking Clinical Trial session at ACC.26 in New Orleans.</description>
                    <pubdate>1774818180000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Trilogy TAVI For Native Aortic Regurgitation: Insights From the ALIGN-AR Trial</title>
<link>/Latest-in-Cardiology/Articles/2026/03/18/11/31/Trilogy-TAVI-For-Native-Aortic-Regurgitation</link>                    <description>The ALIGN-AR (TAVR With JenaValve for Symptomatic Aortic Regurgitation in High Surgical Risk Patients) trial findings demonstrated that, among patients with symptomatic moderate-to-severe or severe native aortic regurgitation (AR) at high surgical risk, transcatheter aortic valve implantation (TAVI) using the Trilogy valve...</description>
                    <pubdate>1773930000000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: Can Moderate Wine Intake Reduce CV Risk?</title>
<link>/Latest-in-Cardiology/Articles/2026/03/04/14/11/eagles-eye-view-04mar2025</link>                    <description>In this week&#226;€™s View, Dr. Eagle looks at increased one-year mortality in younger patients undergoing transcatheter aortic valve replacement (TAVR).</description>
                    <pubdate>1772636400000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Medtronic Clinician Update on New Evolut Valve Data Reinforces Need For Patient Dialogue</title>
<link>/Latest-in-Cardiology/Articles/2026/02/26/17/54/Medtronic-Clinician-Update-on-New-Evolut-Valve-Data-Reinforces-Need-For-Patient-Dialogue</link>                    <description>Medtronic has issued a letter and developed web resources providing an update on long-term reintervention rates associated with its Evolut R and Evolut PRO transcatheter heart valves, drawing on complete six-year and partial seven-year follow-up data from the Evolut Low-Risk Trial published on Feb. 16 in JACC.</description>
                    <pubdate>1772128800000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: New Guidelines for Treatment of Acute PE</title>
<link>/Latest-in-Cardiology/Articles/2026/02/24/16/30/eagles-eye-view-24feb2025</link>                    <description>In this week&#226;€™s View, Dr. Eagle looks at findings from the Evolut Low Risk trial in which self-expanding transcatheter aortic valve replacement (TAVR) versus surgery at six years in low-risk patients with aortic stenosis (AS) is considered.</description>
                    <pubdate>1772031600000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Increased One-Year Mortality in Younger Patients Undergoing TAVR | NCDR Study</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/02/20/14/58/Increased-One-Year-Mortality-in-Younger-Patients-Undergoing-TAVR-NCDR-Study</link>                    <description>Patient case-mix for TAVR has evolved to include more low-risk candidates since the 2019 indication expansion, and younger patients, while more likely to be classified as low-risk, exhibit increased one-year mortality after risk adjustment, according to a Brief Report recently published in JACC.</description>
                    <pubdate>1771599480000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>EVOLUT LOW RISK: Self-Expanding TAVR vs. Surgery at Six Years in Low-Risk Patients With AS</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/02/13/21/24/EVOLUT-LOW-RISK-Self-Expanding-TAVR-vs-Surgery-at-Six-Years</link>                    <description>Six years after undergoing either surgery or TAVR with a CoreValve, Evolut R or Evolut PRO, low-risk patients with aortic stenosis (AS) experienced no significant differences in terms of all-cause mortality or disabling stroke, according to findings from the Evolut Low Risk trial published in JACC. However, researchers observed higher reintervention rates among those assigned to TAVR compared with surgery, largely due to increased incidence of aortic regurgitation (AR).</description>
                    <pubdate>1771254000000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Noninvasive Predictors of LA Compliance Post TMVT</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/02/09/18/56/Noninvasive-Predictors</link>                    <description>In patients with severe mitral regurgitation (MR), low left atrial (LA) reservoir strain (LASr) and prior atrial fibrillation (AFib) intervention or LA appendage (LAA) ligation may predict low invasive LA compliance and limited V-wave reduction after transcatheter mitral valve therapy (TMVT)...</description>
                    <pubdate>1770667920000</pubdate>
                    <category>Articles and Stories</category>
                </item>

    </channel>
</rss>